Gufic Biosciences Share Price

Gufic Biosciences Share Price

NSE: GUFICBIO
|
Pharmaceuticals
|
S Cap
₹ 439.90
+₹14.40 (3.38%)
1D
Last updated 18 Sep, 2026, 15:29 IST

Gufic Biosciences Share Price Today

As of 19 Sep 2026, Gufic Biosciences share price is ₹439.90. The stock opened at ₹422.30, compared to its previous close of ₹425.50. During today's trading session, Gufic Biosciences share price moved in the range of ₹422.30 to ₹439.90, with an average price of ₹431.10 for the day. Looking at its last 52-week, the stock has touched a low of ₹268.00 and a high of ₹467.80. On the performance front, Gufic Biosciences share price has increased by 44.80% over the last six months and is up 20.34% on a year-on-year basis.

₹422.30
3.38% up today
₹439.90
1D LOW
1D HIGH

Gufic Biosciences Returns Calculator

Circuit
L
H
₹348.80
₹523.20
52-week
L
H
₹268.00
₹467.80

About Gufic Biosciences

Gufic Biosciences Share Price
ISIN
INE742B01025
Sector Market Cap
₹ 4,273.54 Cr

Gufic Biosciences Limited is an India-based company, which is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The Company operates in the pharmaceutical segment. It has pharmaceutical products under categories, such as Criti Care, including Doxific, Micafung, Rabol and Tigefic-Plus; Criticare Life, including Ticofic-200 and Gufivan-500; Ferticare, including Puregraf 75IU 3D, Cetrocare 0.25mg 3D and Follicare 150IU 3D; Spark, including Aznee Duo, Eclin, Flabone, Vipro M and Zad G; Herbal, including Bocomo-Forte, Sallaki-Liniment, Zulcer Cap and Smashit tablet, and Aesthaderm, including Prosil, Moiseta Face Wash and Revanox Serum. Its personal care products include StretchNil, Shapers-Natural Feel, Shaper-DryFeel and RollOn. Its products under active pharmaceutical ingredient (API)/bulk drugs include Micafungin, Anidulafungin, Sulconazole and Everolimus. Its Gufic Stridden includes Irvical and Eve.

Gufic Biosciences Financial Highlights

  • Revenue: Gufic Biosciences reported revenue of ₹946.67 crore in FY26 vs ₹823.44 crore in FY25. It showed an increase of 14.97% on a yearly basis.
  • Operating Profit: Gufic Biosciences reported an operating profit of ₹86.55 crore in FY26 vs ₹94.14 crore in FY25. It showed a decrease of 8.06% on a year-on-year basis.
  • Net Profit: Gufic Biosciences reported a net profit of ₹64.21 crore in FY26 vs ₹69.65 crore in FY25. It showed a decrease of 7.81% on a yearly basis.

Gufic Biosciences Quarterly Result Highlights

  • Gufic Biosciences reported revenue of ₹261.28 crore in Jun 2026, compared with ₹250.65 crore in Mar 2026, representing an increase of 4.24% on a quarter-on-quarter (QoQ) basis.
  • Gufic Biosciences reported an operating profit of ₹30.04 crore in Jun 2026, compared with ₹28.95 crore in Mar 2026, representing an increase of 3.77% on a quarter-on-quarter (QoQ) basis.
  • Gufic Biosciences reported a profit of ₹22.31 crore in Jun 2026, compared with ₹21.90 crore in Mar 2026, reflecting an increase of 1.87% on a QoQ basis.
  • The earnings per share (EPS) of Gufic Biosciences stood at ₹6.40 during Jun 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.

Know more
Promoters
72.50%
FII
0.46%
Other DII
0.24%
Retail and other
23.36%
Mutual funds
3.43%
Foreign Institutional Investor (FII)
FII shareholding by period
Sep 20250.34%
Dec 20250.44%
Mar 20260.42%
Jun 20260.46%
Mkt Cap Cr
4,368.31
P/E
59.51
P/B
6.57
ROE
9.66%
D/E
0.61
ROCE
11.45%
Div. Yield
0.02%
EPS(TTM)
6.30
Turnover
0.73
EV/EBITDA
27.55
Net Margin
6.71%
Op. Margin
16.26%
ROA
5.47%
Quick Ratio
0.92
Curr. Ratio
3.44
Based on fundamentals, this stock's
Step 5 of 5
Performance
Excellent
Gufic BioScience outperforming all market indices
Step 1 of 5
Valuation
Overvalued
Gufic BioScience appears overvalued compared to its peers
Step 4 of 5
Earnings
Good
Gufic BioScience revenue, operating profit and net profit are growing
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROED/EROCEBook ValueDiv. YieldTurnoverEPS(TTM)
Sun Pharmaceutical Industries4,40,398.0036.355.2713.74%0.6117.33%93.240.87%0.4810.90
Divis Laboratories2,48,664.0085.0214.8415.32%0.0019.56%629.490.32%0.5598.19
Torrent Pharmaceuticals1,82,738.0084.7621.7325.49%1.6913.85%222.760.70%0.4958.70
Zydus Lifesciences1,15,012.0025.044.2418.59%0.3117.35%237.300.09%0.3335.38
Cipla1,10,794.0033.023.2211.27%0.0014.95%423.360.95%0.4543.52
Laurus Labs1,05,645.0096.8919.9316.77%0.4016.14%97.200.10%0.6713.72
Dr. Reddy's Laboratories97,749.4030.712.5711.07%0.1812.54%377.950.68%0.4138.68
Aurobindo Pharma99,828.1026.902.639.25%0.1911.76%394.820.23%0.3841.58
Lupin98,069.8017.674.3723.76%0.0424.88%659.000.84%0.57129.18
Mankind Pharma95,743.9046.305.8711.74%0.3413.13%396.980.04%0.4449.37

Auto-generated based on historical fundamentals; not a recommendation to buy/sell.

Gufic Biosciences Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024
Revenue₹944.01₹819.81₹806.67
Other Income₹2.66₹3.63₹2.18
Total Revenue₹946.66₹823.43₹808.84
Total Expenses₹860.12₹729.29₹693.17
Profit Before Tax₹86.55₹94.14₹115.67
Tax₹22.34₹24.49₹29.54
Profit After Tax₹64.21₹69.65₹86.14
EPS - Basic₹6.40₹6.95₹8.74
EPS - Diluted₹6.40₹6.95₹8.74

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024
Profit before tax₹64.21₹69.65₹86.14
Income before WC changes₹151.81₹137.94₹149.82
Change in Assets-₹131.09-₹9.02-₹170.27
Change in Liabilities₹36.26₹16.46₹40.04
Change in WC-₹94.83₹7.44-₹130.23
Cash flow from Operations₹45.14₹122.57-₹7.46
Cash flow from Investing-₹30.96-₹70.78-₹102.39
Cash flow from Financing₹32.29-₹37.20₹82.38
Total Cash Flow₹46.46₹14.59-₹27.47
Cash (Start of the year)₹15.72₹1.14₹28.60
Cash (End of the year)₹62.19₹15.72₹1.14

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024
Non-Current Assets₹540.26₹544.84₹492.06
Current Assets₹802.12₹624.52₹600.48
Total Assets₹1,342.37₹1,169.36₹1,092.54
Current Liabilities₹517.85₹387.56₹372.05
Net Current Asset₹284.27₹236.97₹228.43
Non-Current Liabilities₹159.54₹180.73₹187.93
Equity Capital₹664.99₹601.08₹532.56
Total Equity & Liabilities₹1,342.37₹1,169.36₹1,092.54

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹940.48₹819.81₹806.67₹690.62
Other Income₹2.58₹3.62₹2.18₹2.57
Total Revenue₹943.06₹823.42₹808.84₹693.19
Total Expenses₹857.57₹728.99₹693.17₹586.47
Profit Before Tax₹85.49₹94.43₹115.67₹106.72
Tax₹22.34₹24.49₹29.54₹27.02
Profit After Tax₹63.15₹69.93₹86.14₹79.70
EPS - Basic₹6.30₹6.97₹8.74₹8.22
EPS - Diluted₹6.30₹6.97₹8.74₹8.22

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹63.15₹69.93₹86.14₹79.70
Income before WC changes₹150.74₹138.22₹149.82₹136.36
Change in Assets-₹131.13-₹9.08-₹170.27-₹123.21
Change in Liabilities₹36.42₹16.44₹40.04-₹12.05
Change in WC-₹94.71₹7.37-₹130.23-₹135.25
Cash flow from Operations₹44.19₹122.78-₹7.46-₹26.59
Cash flow from Investing-₹30.96-₹71.79-₹102.40-₹190.73
Cash flow from Financing₹32.19-₹37.20₹82.38₹234.31
Total Cash Flow₹45.42₹13.78-₹27.48₹16.99
Cash (Start of the year)₹14.91₹1.13₹28.60₹11.61
Cash (End of the year)₹60.32₹14.91₹1.13₹28.60

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹541.33₹545.85₹492.07₹397.05
Current Assets₹800.26₹623.78₹600.47₹464.11
Total Assets₹1,341.59₹1,169.63₹1,092.54₹861.16
Current Liabilities₹517.87₹387.53₹372.05₹288.21
Net Current Asset₹282.39₹236.24₹228.42₹175.90
Non-Current Liabilities₹159.54₹180.73₹187.93₹225.14
Equity Capital₹664.18₹601.36₹532.56₹347.81
Total Equity & Liabilities₹1,341.59₹1,169.63₹1,092.54₹861.16
* All values are in INR Crore
Qty
Bid
0
0
0
0
0
0
0
0
0
0
Ask
Qty
436
1
0
0
0
0
0
0
0
0
Bid Total: 0
Ask Total: 1
Buy orders: 0%
Sell orders: 100%
Bearish
1
Neutral
6
Bullish
1
Neutral
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict
RSI (14)
58.06
Neutral
ATR (14)
18.22
Neutral
STOCH(9,6)
50.08
Neutral
STOCH RSI (14)
49.67
Neutral
ADX(9)
23.71
Bearish
UO(9)
53.14
Neutral
ROC(12)
3.55
Bullish
WillR(14)
-43.71
Neutral
Period
Simple value
Exponential vaue
5D
426.31
428.88
10D
431.63
428.43
20D
426.1
425.58
50D
411.28
409.86
100D
374.81
384.44
Volume trend — traded volume by day
18 Sep0L
17 Sep0L
16 Sep1L
15 Sep0L
Average0L

Technical indicators used here are for indicative purposes only. Kindly do not treat it as an investment or trading advice

Compare against other stocks
Gufic Biosciences Share Price
Gufic Biosciences
Pharmaceuticals
Add Stock
Add Another

Gufic Biosciences Share Price FAQs

Gufic Biosciences share price data is sourced from NSE/BSE and may be delayed. It is displayed for informational purposes only and does not constitute investment advice or a recommendation to buy or sell.

Trusted by 2 Crore+ Indians for their wealth-building needs. SEBI Registered Broker. SEBI Reg No. INZ000315837